AMPLIA THERAPEUTICS LIMITED — Investor Relations & Filings

Amplia Therapeutics Limited is a clinical-stage pharmaceutical company focused on the development of small molecule inhibitors of Focal Adhesion Kinase (FAK). The company's primary asset, narmafotinib (AMP945), is a potent and highly selective FAK inhibitor designed to treat solid tumors and fibrotic diseases. Narmafotinib is currently undergoing clinical evaluation for the treatment of advanced pancreatic cancer, where it aims to reduce the fibrotic stroma that protects tumors and limits the effectiveness of standard-of-care chemotherapy. Amplia is also investigating the application of its FAK inhibitor platform in idiopathic pulmonary fibrosis (IPF). The company's pipeline includes AMP886, which targets FAK as well as VEGFR3 and FLT3. The core business strategy involves leveraging targeted kinase inhibition to address significant unmet needs in oncology and chronic fibrosis.